Landos Biopharma, the Blacksburg, Virginia clinical-stage biopharmaceutical company recently raised $60 million in a round of fundraising.
The Series B round was co-led by RTW Investments and Perceptive Advisors. New investors Osage University Partners and PBM Capital also participated in the fundraising. Proceeds from the funding will go to support Landos’ Phase 2 global clinical trials for BT-11 which is an oral, gut-restricted small molecule therapeutic that targets a novel pathway called Lanthionine Synthetase C-Like 2 (LANCL2)...
Sorry, you need to subscribe to read this article.
If you would like to access this article, please subscribe below.
Premium subscribers receive complete access to our site content which includes market research and insights as well as coverage of the most important news, issues and events related to the healthcare technology industry.